A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

Trial Profile

A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

Recruiting
Phase of Trial: Phase I

Latest Information Update: 16 Mar 2018

At a glance

  • Drugs MGD 013 (Primary)
  • Indications Haematological malignancies; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors MacroGenics
  • Most Recent Events

    • 27 Feb 2018 According to a MacroGenics media release, the company expects to establish the dose and schedule for MGD013 administration as well as initiate dose expansion cohorts in 2018.
    • 10 Nov 2017 According to a MacroGenics media release, results from this trial will be presented at the 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting.
    • 05 Sep 2017 According to a MacroGenics media release, the first patient has been dosed in this trial.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top